April 20, 2022
1 min watch
Save
VIDEO: Nyxol trial shows positive results for mydriasis reversal
NEW YORK – A phase 3 FDA registration trial for Ocuphire Pharma’s Nyxol yielded positive topline results for the reversal of mydriasis, according to a company executive.
Bindu Manne, who heads up market development and commercialization for Ocuphire, said the preservative-free eye drop formulation of phentolamine mesylate is also being studied for presbyopia and night vision disturbances.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Manne reports being employed by Ocuphire Pharma.
Read more about